End-Stage Renal Disease (ESRD)

Trending

View All

Aug 30, 2022

Aktis’s Novel Targeted Alpha Radiopharmaceuticals; Koye Partners with Sonde Health; Novartis to Spin Off Sandoz Business; Alcon to Buy Aerie Pharma; Fast Track Designation to Merck’s MK-2060; FDA Approves Ibrutinib for Chronic GvHD; French Authorities Clears BrainVectis’s Clinical Trial; Takeda’s Dengue Vaccine TAK-003 Gets Approval in Indonesia

Aktis Oncology Raises USD 84 Million To Advance Novel Targeted Alpha Radiopharmaceuticals Aktis Oncology has raised an additional USD 84 million in its Series A round, adding to the USD 72 million raised last year to help bring its radiopharmaceuticals to market. The extension to the first round included Merck's...

Find More

Editor's Pick

Wainua – The Only Approved Medicine for hATTR-PN Treatment

lyfgenia-or-casgevy-for-sickle-cell-disease-treatment

Lyfgenia or Casgevy: Who Will Lead the Sickle Cell Disease Treatment Space?

Another Feather in the Cap for Xtandi and Keytruda — The Two Main Cancer Drugs

vabysmo-for-retinal-vein-occlusion-treatment

Roche’s Vabysmo Third US Approval Spiced Up the Battle With Regeneron and Bayer’s Eylea

AAV Gene Therapies for Hemophilia B Treatment: The Road to a Cure

Newsletter/Whitepaper

ASCO Conference 2023

The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.

Catch the Glimpse here

By DelveInsight

End-Stage Renal Disease (ESRD)

Search by Categories

Our expertise in the industry

View All

Editor's Pick

Newsletter/Whitepaper

ASCO Conference 2023